Skip links

Say Hi to Hybrid

Jump To Section

Higher productivity, better employee retention, lower operating costs, and reduced carbon emissions were some of the many benefits engendered by the great telecommuting experiment during the covid pandemic.

Say Hi to Hybrid

Higher productivity, better employee retention, lower operating costs, and reduced carbon emissions were some of the many benefits engendered by the great telecommuting experiment during the covid pandemic.

Additionally, with all workers occupying equal-sized rectangles and accessing the same volume controls in video calls, the pandemic was also seen as a great leveler that gave everyone an equal platform to perform and destigmatize the dreaded practice of working from home.

Will this really be covid’s legacy?

The answer to this question will wholly depend on what happens next.

With offices around the world gradually opening up, a hybrid workplace is surely becoming the new normal.

A hybrid working model, in most setups, gives employees a fair amount of freedom to choose when and for how long they would like to be physically present in the office. With such a privilege at the employees’ disposal, this new system is being touted as the sweet spot between the complete online and the complete offline working models and consequently, the sure-shot path to organizational success.

But there is more to this than what meets the eye.

Impartiality and rectitude are easier to sustain when everyone is working in similar circumstances.

If left to develop organically, the hybrid workplace is more likely to exacerbate existing inequalities between workers than reduce them.

People have different preferences about office work, and those differences are not distributed randomly.

Given a choice, women and parents of young children would usually prefer to work remotely.

Our innate human biases make us subconsciously prefer physical presence, and employers are no exception to this.

So how to do hybrid, right?

Workplaces need to be engineered to ensure fairness. Organizational policies should be spelled out such that they benefit both remote-working employees and in-house team members alike, even if they look slightly different
Situations where physical presence adds genuine value should be well defined and clearly communicated to one and all.
Physical proximity should never be conflated with productivity, much less with credibility or meritoriousness.
Use of technologies that enhance communication and co-ordination should be advocated.
Asynchronous communication should be normalized. Team members should be enabled with all the resources needed to complete a task without the requirement to be connected 24/7.

As a thumb rule, cross-company schemes and strategies should be established by concurrently accounting for all types of workers instead of tending to offline workers first and then to online workers as an afterthought.

Covid has demonstrated the efficacy of telecommuting, and a hybrid work model is here to stay.

With some planning and preparation, this model can be harnessed to achieve remarkable success both to the organization and the workforce it encompasses.

Aparna Prabhu

Aparna Prabhu

Latest Reads


Suggested Reading

Ready to Unlock Yours Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes